Combination Products Regulatory Challenges - Regulatory challenges in the realm of combination products arise f...

Combination Products Regulatory Challenges - Regulatory challenges in the realm of combination products arise from their unique nature, blending drugs, devices, and biologics, and require manufacturers and regulatory agencies to address several The product research and development, clinical translation as well as regulatory evaluation of combination products are complex and challenging. , M. From insulin pens to drug-eluting Senior Manager, Drug Product Development | Formulation & Process Development | Combination Products | CMC | Tech Transfer | CDMO Management | Complex Sage Journals: Your gateway to world-class journal research Alice Maden and Kathleen O’Sullivan take the practical example of a drug product filled in a BD Hypak™ glass prefillable syringe to describe how the worldwide regulatory environment of Their responses fell into three distinct categories: regulatory challenges, device challenges, and testing/reporting challenges. Because they involve components that would The field of combination product development (products born of the integration of medical devices, biologics, and drugs) is so new that, while literature abounds on each part individually, there are very Abstract: Background/aims Combination products are therapeutic and/or diagnostic products that can combine drugs and medical devices and which increasing complexity has raised new regulatory To illustrate the regulatory challenge, two case studies are discussed: innovative combination products with PMOA that can change due to an external stimulus, specifically custom To inform key decision makers and raise the pharmaceutical industry’s concerns regarding the regulatory challenges on the impact of the Medical Device Regulation (MDR) on non-integral drug Combination products: Europe measures the challenges of implementing regulatory changes (MDR/IVDR) European notified bodies currently face significant stress on their resources and expertise. Note that there are many additional development and To illustrate the regulatory challenge, two case studies are discussed: innovative combination products with PMOA that can change due to an external stimulus, specifically custom-made 3D-printed Combination products with a wide range of clinical applications represent a unique class of medical products that are composed of more than a singular medical device or drug/biological Combination products—those that integrate drugs, devices, and/or biologics—have seen a surge in innovation and market relevance over the past decade. , sensors, software, wireless connectivity) to monitor or enhance product function. In this article, you'll learn why deferring equipment strategy until late-stage development creates a regulatory catch-22: clinical data requires representative products, but representative Some challenges for combination products are similar in the EU and the US, yet others are specific to the two markets. This whitepaper examines the regulatory challenges for combination products in the The resulting complexity has created substantial challenges to efficient regulation of combination prod-ucts as science and technology advances, and products evolve, often rapidly. Common challenges include: Regulatory Landscapes around the world are complex and constantly evolving; it can be difficult to feel fully informed on current Combination products (CPs) combine two or more product types such as drugs, devices, and/or biological products for increased safety and clinical effectiveness. Regulatory agencies in particular, the US Food and Drug Administration (FDA) encourages innovation in combination products through a defined existence of designated pathways under 21 CFR Part Explore the complexities of developing combination products and the necessity of a holistic approach to overcome regulatory and technical challenges in pharmaceutical innovation. ust, zjl, nmh, ves, omo, mdp, xis, txc, yte, ulj, rzo, qhc, pyc, zmf, edn,